🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🌟Great presentation by Chadi Hage Chehade at #ASCO25!! Utilization and timing of NGS in pts w/ 5 most common cancers in the US👉Many pts either don’t receive NGS or have the first NGS very late 👇ASCO OncoAlert Neeraj Agarwal, MD, FASCO Umang Swami Flatiron Health UroToday.com

Just in from ASCO #ASCO25 👉📢 Finally a T-cell engager in #prostatecancer mCRPC with minimal CRS syndrome (only grade 1, all outpatient dosing) and promising efficacy👇 Congrats #drbaldini Mark Stein and team Journal of Clinical Oncology OncoAlert UroToday.com PCF Science

Just in ASCO #ASCO25 👉oral presentation 👉Efficacy of enzalutamide+talazoparib vs enza in the ph3 TALAPRO-2 trial extends beyond BRCAm subgroup in mCRPC #prostatecancer 👇Congrats DrZschaebitz OncoAlert UroToday.com Median OS significantly improved in patient cohort with HRRm

Great poster session this morning with Nicolas Sayegh, MD highlighting work in #prostatecancer TMB & MSI-H w/ real world IO outcomes Foundation Medicine! Truly a star resident UTSW Simmons Cancer Center UTSW Internal Medicine co-mentored by me & Neeraj Agarwal, MD, FASCO. Look out for his fellowship apps this fall! #ASCO25

👉🏻 Superstar Zeynep Irem Ozay, MD presenting ASCO our real-world data showing lutetium has better survival outcomes than cabazitaxel in post-ARPI/docetaxel mCRPC patients. #ASCO25 ASCO #ProstateCancer GU Cancer Research Program @HuntsmanCancer Neeraj Agarwal, MD, FASCO OncoAlert UroToday.com

🌟Great poster presentation by Nicolas Sayegh, MD at #ASCO25! Real-world pts with mCRPC👉TMB-H (without MSI-H) & MSI-H have similar outcomes on ICI Flatiron Health MSI-H detected by ctDNA is a predictive biomarker Neeraj Agarwal, MD, FASCO Ryon Graf, PhD Umang Swami UTSW Simmons Cancer Center OncoAlert UroToday.com

Breaking news @asco #ASCO25 👉 results of the phase 3 trial in localized prostate cancer with CAN-2409+ pro drug👉meets primary end point 👉 improves disease-free survival, well tolerated, ADT use balanced. OncoAlert UroToday.com PCF Science

Congrats Michael Ong for the stellar talk ASCO #ASCO25 👉 PSA response (<0.2 ng/ml) after starting ADT+ARPI in mHSPC #prostatecancer (occurred in 50% of pts) associated with ⬆️OS (& 5-fold ⬆️ in death if PSA is >\=0.2). OncoAlert UroToday.com PCF Science Dan George

Niraparib plus Abi delays rPFS in HRR+ particularly BRCA2m mHSPC in AMPLITUDE! #ASCO25 #MedIQASCO25 HR 0.63 is clinically meaningful.

Breaking news ASCO #ASCO25 👉 1st biomarker selected, positive ph3 trial in mHSPC #ProstateCancer 👉Abiraterone+ niraparib/PARPi significant improve rPFS (favorable OS trend) in HRR+ pts (⬆️benefit in BRCApts), NGS testing must inall AttardLab PCF Science UroToday.com OncoAlert

Stellar presentation ASCO #ASCO25 by trailblazer Rana McKay, MD, FASCO on ETCTN trial with radium +|- olaparib in mCRPC #prostatecancer 👉rPFS ⬆️ with the combo w/wo HRRm👇Data continues to reinforce role of PARPi in rationale combinations Toni Choueiri, MD (mentor), UroToday.com OncoAlert

Just in Clinical Cancer Research 👉Congrats Chadi Hage Chehade Umang Swami & GU Cancer Research Program @HuntsmanCancer team👉Poor outcomes w/ SOC Rx in mHSPC #prostatecancer w/HRRm in 637 real-world US pts👇 Flatiron Health Foundation Medicine Ryon Graf, PhD 👉 need to add PARPi 👉free link: bit.ly/3TsOw9i OncoAlert UroToday.com

Excited to see our work published in Clinical Cancer Research ! Real-world pts w/ mHSPC #prostatecancer w/ HRRalt had worse survival than those w/ non-altered HRR 👉bit.ly/3TsOw9i👇 Grateful for terrific support from team Ryon Graf, PhD Umang Swami Neeraj Agarwal, MD, FASCO UroToday.com OncoAlert

Association of Homologous Recombination Repair Alterations With Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer aacrjournals.org/clincancerres/… Research has shown that around 30% of advanced #ProstateCancer patients have Homologous Recombination / DNA Damage

✏️Neeraj Agarwal, MD, FASCO, Chadi Hage Chehade, and Georges Gebrael discuss the STAMPEDE trial in their linked comment See here: thelancet.com/journals/lanon…

Metformin did not boost survival in metastatic hormone-sensitive prostate cancer. It did ease ADT’s metabolic side effects. Not a game-changer, but still some hope for patient quality of life. #Oncology With very nice editorial by Georges Gebrael Chadi Hage Chehade and Neeraj Agarwal, MD, FASCO

Breaking News from ph3 Embark trial👉Enzalutamide+ADT improve overall survival (OS) vs. ADT alone in Non-Metastatic HSPC #Prostatecancer Congrats to Stephen Freedland, MD neal shore & team! Earlier enza works better! Link👉 rb.gy/iyc3f2 OncoAlert UroToday.com Prostate Cancer Foundation

Hats off to Regina Barragan-Carrillo who (w Zeynep Zengin Yale Internal Medicine) put together a beautiful overview of #microbiome modulation for the treatment of #solidtumors in Journal of Clinical Oncology. Citing work from innovative #scientists & #trialists in the field like #Routy, #ElKrief, lisaderosa, #Zitvogel,

Just came online in The Lancet 👉Our two papers on improved OS with Enzalutamide + Talazoparib in mCRPC #ProstateCancer in all-comer & HRRm patients (Median OS and HRs👇). Weblinks to the papers👉 bit.ly/4lXkLtB and bit.ly/4nNIyOh Prostate Cancer Foundation UroToday.com OncoAlert

A very informative and detailed discussion on practice changing data and trial updates in bladder cancer by Petros Grivas #BestOfASCO 2025 in Boise! education.binaytara.org/content/best-a…